Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo

Clinics

Volumn 68, Issue 5, 2013, Pages 694-701

  Lu, Wei Dong ^a   Qin, Yong ^b   Yang, Chuang ^c   Li, Lei ^a   Fu, Zhong Xue ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b People's Hospital of Bishan County   (China)

^c Third People's Hospital of Mianyang City   (China)

Author keywords

Colorectal Carcinoma; Curcumin; Multidrug Resistance; Reversal

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL SURVIVAL; COLON TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; MOUSE; MULTIDRUG RESISTANCE; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COLONIC NEOPLASMS; CURCUMIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; TUMOR CELLS, CULTURED;

EID: 84878459530     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(05)18     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. Ca-Cancer J Clin. 2005;55(2):74-108.
2. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97(1):72-81.
3. Song M, Zang W, Zhang B, Cao J, Yang G. GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells. J Exp Clin Canc Res. 2012;31.
4. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia. 2000;14(3):467-73, http://dx.doi.org/10.1038/sj.leu.2401694.
5. Roninson IB. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem. Pharmacol. 1992;43(1):95-102.
6. Shabbits JA, Mayer LD. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol. Cancer Ther. 2002;1(3):205-13.
7. Shan JZ, Xuan YY, Ruan SQ, Sun M. Proliferation-inhibiting and apoptosis-inducing effects of ursolic acid and oleanolic acid on multidrug resistance cancer cells in vitro. Chin J Integr Med. 2011;17(8):607-11.
8. Lin JK, Lin-shiau SY. Mechanisms of cancer chemoprevention by curcumin. Proc Natl Sci Counc Roe(B). 2001;25(2):59-66.
9. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin. 2005;26(8):1009-16, http://dx.doi.org/10.1111/j. 1745-7254.2005.00149.x.
10. Chaudhary PM, Roninson IB. Expression and activity of Pglycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991;66(1):85-94, http://dx.doi.org/10.1016/0092-8674(91)90141-K.
11. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96, http://dx.doi.org/10.3322/CA. 2007.0010.
12. Kuttan R, Bhannmathy P, Nirmala K, George MC. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985;29(2):197-202, http://dx.doi.org/10.1016/0304-3835(85)90159-4.
13. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Tima S, Chanarat P, Limtrakul P. Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch Pharm Res. 2006;29(10):866-73, http://dx.doi.org/10.1007/BF02973907.
14. Xiao H, Xiao Q, Zhang K, Zuo X, Shrestha UK. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol. 2010;89(4):399-404, http://dx.doi.org/10.1007/s00277-009-0831-6.
15. Lu JJ, Cai YJ, Ding J. The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells. Mol Cell Biochem. 2012;360(1-2):253-60, http://dx.doi.org/10.1007/s11010-011-1064-2.
16. Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer. 2004;4:13, http://dx.doi.org/10.1186/1471-2407-4-13.
17. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol. 2002;64(4): 573-82, http://dx.doi.org/10.1016/S0006-2952(02)01224-8.
18. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J, et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer. 2009;125(9):2187-97.
19. Van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van der Heiden IP, Wiemer EA, Vossebeld PJ, et al. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther. 2006;80(5):427-39, http://dx. doi.org/10.1016/j.clpt.2006.07.005.
20. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411-24, http://dx.doi.org/10.1634/theoncologist.8-5-411.
21. Al-Awqati Q. Regulation of ion channels by ABC transporters that secrete ATP. Science. 1995;269(5225):805-06, http://dx.doi.org/10.1126/ science.7543697.
22. Chen BA, Shan XY, Chen J, Xia GH, Xu WL, Schmit M. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line. Chin J Cancer. 2010;29(6):591-5.
23. Shi LX, Ma R, Lu R, Xu Q, Zhu ZF, Wang L, et al. Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. Cancer Lett. 2008;269(1):101-10, http://dx.doi.org/10.1016/j.canlet.2008.04.033.
24. Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Ahi Z, et al. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol. 2004;56(8):1061-6, http://dx.doi.org/10.1211/ 0022357043879.
25. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997;3(8):917-21, http://dx.doi.org/10.1038/nm0897-917.
26. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580-4.
27. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerg-ing role in cancer. Oncogene. 1998;17(25):3247-59.
28. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58(23):5315-20.
29. Deveraux QL, Reed JC. IAP family proteins--suppressors of apoptosis. Genes Dev. 1999;13(3):239-52, http://dx.doi.org/10.1101/gad.13.3.239.
30. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005;24(15):2474-82, http://dx.doi.org/10.1038/sj.onc.1208490.
31. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci. 2002;99(7):4349-54, http://dx.doi.org/10.1073/pnas.072586399.
32. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys. 2003;55(5):1341-7, http:// dx.doi.org/10.1016/S0360-3016(02)04618-7.
33. Wang ZH, Xie YH, Wang HB. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther. 2005;4(7):716-9.
34. Ikeguchi M, Liu J, Kaibara N. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis. 2002;7(1):23-9, http://dx.doi.org/10.1023/A:1013556727182.